All News
Best of 2023: Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
Read Article
Best of 2023: Our old friend, hydroxychloroquine
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
Read Article
ICYMI: Effective Treatments for Rheumatoid Arthritis ILD
The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.
Read Article
ICYMI: Bimekizumab is Coming…in Third Place
Of the many exciting advancements for patients with psoriatic arthritis at ACR23 one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab.
https://t.co/rhyEuyCjQI https://t.co/vbRs2144We
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Methotrexate: shall we split up?
Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg.
https://t.co/EQV2LeaaGB https://t.co/bD2zJbXETv
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/7SgvYqFe1W
Dr. John Cush RheumNow ( View Tweet)
Promising Therapies for Sjogren's
Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/qwRRf0sYhj https://t.co/zZACPJ96NM
Dr. John Cush RheumNow ( View Tweet)
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/NL8yJ9CdvQ https://t.co/dUUXyWYbsT
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Eosinophilia in RA
High Eosinophil counts in Stable RA - what's the differential Dx?.
https://t.co/r7DHil4u9B https://t.co/rTAGUcgd1C
Dr. John Cush RheumNow ( View Tweet)
Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/xOYfEs16ou https://t.co/MzEPpUc7Eb
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Recommendations on Fatigue
Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life.
https://t.co/ETYyCnykj7 https://t.co/c2DEWrvqZb
Dr. John Cush RheumNow ( View Tweet)
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/iBIreoNrXx https://t.co/xh4rWdKbGT
Dr. John Cush RheumNow ( View Tweet)
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/rJSqLwQW1S https://t.co/w3ZpdVQYNL
Dr. John Cush RheumNow ( View Tweet)
Hemophagocytic Lymphohistiocytosis in Still's disease
Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/8XvMsGtul2 https://t.co/HG0QOu5V77
Dr. John Cush RheumNow ( View Tweet)
FDA Warning on CAR-T Cell Therapy
The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
https://t.co/uxY7xgqgqn https://t.co/xyZrXXGGIy
Dr. John Cush RheumNow ( View Tweet)
Korean ULTRA registry studied 117 Gout pts starting ULT; compared T2T achievers (SUA< 6) vs non-achievers. @6 mos, 71% reached target SUA (w/ better adherence (98% vs. 76%) than non-achievers. T2T achievers assoc w/ good adherence, +FamHx, & HTN meds https://t.co/wTuvPqcan5 https://t.co/QD9j923sSa
Dr. John Cush RheumNow ( View Tweet)
Metanalysis shows the prevalence of self-reported sleep problems in #PsA ranged 30% to 85%. 6 studies showed poor sleep quality in 73% (statistically higher than controls 27%). Sleep ranked in the top 4 health-related quality of life domains by PsA pts. https://t.co/d79Ji3KCBu https://t.co/HJpqUIQ8x6
Dr. John Cush RheumNow ( View Tweet)
FINAL DAY for early bird pricing for RheumNow Live.
Take advantage of this discounted price TODAY!
https://t.co/UW9SMjEBYB https://t.co/DX2SJZYkUW
Links:
Dr. John Cush RheumNow ( View Tweet)
Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/Hhxr7hscaL https://t.co/J46JvHwRmc
Dr. John Cush RheumNow ( View Tweet)
Clinical Practice Res Database studied 51K gout pts before ULT therapy, 36% had ≥ 1 recurrent flares, 17% flared w/in 12 mos of Dx. Flares risk: Male, blacks, obese, CHF, CKD, CVD, diuretics, Hi SUA (HR 4.6). Only 28% Given ULT w/in 12 mos of Dx https://t.co/TAHBDxA6Th https://t.co/rwztpe7y2r
Dr. John Cush RheumNow ( View Tweet)